Single Center Evaluation of Long-Term Results of Glargin U-300 in Insulin Naive Patients In a Real-World Setting
Article Sidebar
Main Article Content
Abstract
Objective: Insulin therapy stands as one of the most effective and well-established therapeutic options for managing glycemic control in Diabetes Mellitus (DM). Glargine 300 U/mL (Gla-300) represents a new long-acting insulin analog, which has demonstrated a decrease in the risk of hypoglycemia and a reduction in the total number of injections due to prolonged insulin absorption. In this study, we investigated the long-term effects of Gla-300 on Fasting Plasma Glucose (FPG) and HbA1c levels, as well as the incidence of hypoglycemia in insulin-naive patients admitted to the Internal Medicine outpatient clinic, over a period of 0, 3, 6, 12, and 24 months..
Material and Methods: Between January 2018 and June 2022, insulin-naive patients diagnosed with Type 2 Diabetes Mellitus (T2DM) who initiated treatment with Gla-300 and sought care at the Internal Medicine outpatient clinic were subjected to retrospective analysis.
Results: The study included 49 insulin-naive patients. A statistically significant decrease was observed in Fasting Plasma Glucose (FPG) (p = 0.03) and HbA1c (p = 0.02) levels during the 24-month follow-up period of Glargine U-300. Additionally, a significant reduction in both FPG (p < 0.01) and HbA1c (p < 0.01) values was achieved at the time of diagnosis and at 3 months. Hypoglycemia was reported in only 1 patient (2%) during our study, indicating a very low hypoglycemia rate.
Conclusion: Diabetes mellitus (DM) poses a significant public health challenge, resulting in economic burden and diminished quality of life. Developed to address these challenges, Gla-300 serves as a long-acting basal insulin that effectively reduces the risk of hypoglycemia while offering targeted glycemic control, as evidenced by our study findings. In Turkey, there is a pressing need for multicenter, prospective real-world studies that incorporate parameters such as insulin dosage and weight monitoring.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2024-03-05
Published 2024-03-07
References
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137-149. doi: 10.1016/j.diabres.2013.11.002
Powers AC, D’Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38:S1-S93.
Schaefer CF, Reid TS, Dailey G, et al. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. Postgrad Med. 2014;126:93-105. doi: 10.3810/pgm.2014.10.2824
Lowery JB, Donihi AC, Korytkowski MT. U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes. Diabetes Technol Ther. 2012;14:505-507. doi: 10.1089/dia.2011.0248
Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011;13(suppl 1):S103-S108. doi: 10.1089/dia.2010.0251
Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127:S25-S38. doi: 10.1016/j.amjmed.2014.07.005.
National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 28(12): 1039-57, 1979
Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. Adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, 21: 518-24, 1998.
Harris M.I. Diabetes in America. In: ‘ADA. Annual Review of Diabetes, 1999, 1999, pp. 23-7.
International Diabetes Federation, World Diabetes Foundation. Diabetes Atlas. 2nd Ed. Brussels: International Diabetes Federation Publ.; 2003.
Pick Up J, Williams G. Hypertension and diabetes mellitus. In: Pick Up J, Williams G, editors. Textbook of diabetes. 2nd ed. Oxford: Blackwell Science; 1997. p. 56.1-56.19.
Vinik AI, Nevoret ML, Casellini C, et al. Diabetic neuropathy. Acute and Chronic Complications of Diabetes. Endocrinology and Metabolism Clinics of North America. Eds: Poretsky L, Liao EP, LeRoith D. UK: Elsevier; 2013. p. 747-87.
Çetinarslan B, Nomak G, Ak A. Effectiveness And Safety Of Insulin Glargine 300 U/Ml In Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Oral Antidiabetic Treatment In Turkey (EASE STUDY)- SS-13. 55th Ulusal Diyabet Metobalizma ve Beslenme Hastalıkları Kongresi, 24-24 Nisan 2019.
Galstyan GR, Tirosh A, Vargas-Uricoechea H, et al. Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study. Diabetes Ther. 2022 Jun;13(6):1187-1202. doi: 10.1007/s13300-022-01266-4. Epub 2022 May 9. PMID: 35532858; PMCID: PMC9174390
Yki-Jarvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235-3243. doi:10.2337/dc14-0990
Sussman M, Sierra JA, Garg S, et al. Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med Econ. 2016;19:1099-1106.
Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of Type 2 diabetes mellitus. Diabetes Therapy. 2014;5:225-242.
Korkmaz ÖP, Özgür DS, Karimava G, et al. Tek Merkez Glarjın U-300 Deneyımı: Gerçek Yaşam Çalışması- SS-03. 55th Ulusal Diyabet Metobalizma ve Beslenme Hastalıkları Kongresi, 24-24 Nisan 2019.
Fadini GP, Buzzetti R, Nicolucci A, Larosa M, Rossi MC, Cucinotta D. Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY). Acta Diabetol. 2022:1-14.